Vertex paid a 102% premium — the year's second-highest — to land Crinetics for $10B after being the only bidder, per a new SEC filing.
To gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma’s banner year for M&A. And the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s…
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid…
By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and…
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10…
Crinetics stock nearly doubled Tuesday after Vertex pledged $10 billion to buy the endocrinology-focused biotech.
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and…
